Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Using MRI scans to target biopsies is more effective at detecting prostate cancers that are likely to need treatment than standard ultrasound guided biopsies alone, according to research published on 7 August in JAMA Network Open. The research, led by the National Institute for Health Research (NIHR) and Universities of Bristol, Ottawa, Exeter and Oxford, combined the results from seven studies covering 2,582 patients.

Similar stories

Analysis identifies 50 new genomic regions associated with kidney cancer risk

In a new analysis of genetic susceptibility to kidney cancer, an international team of researchers, including Professor Mark Sullivan from Oxford University's Nuffield Department of Surgical Sciences, has identified 50 new areas across the genome that are associated with the risk of developing kidney cancer.